Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 11/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18550477 | 0.88 | HTR2C (0.56) | HTR2CPRMT5MAOB | |
| SCHEMBL18550162 | 0.84 | HTR2C (0.47) | HTR2CHTR2BPRMT5MAOBNR4A2 | |
| SCHEMBL18549919 | 0.82 | DHFR (0.50) | HTR2CHTR2BMAOBNR4A2MAOA | |
| SCHEMBL18549940 | 0.81 | HTR2C (0.47) | HTR2CHTR2B | |
| SCHEMBL18550085 | 0.78 | HTR2C (0.53) | HTR2CPRMT5MAOBNR4A2CYP1A2 | |
| SCHEMBL18617044 | 0.77 | NR4A2 (0.41) | PRMT5MAOBNR4A2PARP10MAOA | |
| SCHEMBL18549838 | 0.77 | NR4A2 (0.47) | MAOBNR4A2PARP10 | |
| SCHEMBL19711852 | 0.75 | HTR2C (0.50) | HTR2CHTR2B | |
| SCHEMBL18550468 | 0.75 | S1PR5 (0.51) | MAOBNR4A2PARP10 | |
| SCHEMBL18563767 | 0.75 | HTR2C (0.43) | HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| EP-3341369-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017036978-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | ABBVIE INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | HTR2C 835/4885HTR2B 805/4885PRMT5 2839/4885 |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | HTR2C 835/4885HTR2B 805/4885PRMT5 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.